Drugs / 68Ga-MGS5
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06520319 | Jun 2023 → Dec 2024 overdue | medullary thyroid gland carcinoma | First Affiliated Hospital of Fujian Medical University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-MGS5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06520319 ↗ |
| Modality | Diagnostic / imaging agent | “promising for diagnosis and staging of MTC” NCT06520319 ↗ |
| Route | Intravenous | “one intravenous injection of 68Ga-MGS5” NCT06520319 ↗ |